Study S001793

A Phase 4, Open-Label, Single-Arm, 46-Week Study to Investigate the Safety and Efficacy With Tirzepatide in Adult Indian Participants With Either Type 2 Diabetes or Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07438444
Study type: INTERVENTIONAL
Phase: PHASE4
Masking: NONE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 344
Start: 2026-02-27
Primary completion: 2027-07
Lead sponsor: Eli Lilly and Company
Conditions: Diabetes Mellitus, Type 2; Obesity; Overweight
Interventions: DRUG:Tirzepatide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:I8F-IN-GPIZ

Registered primary outcomes

Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration [Baseline through Week 46]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.